Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
This was a primary data collection-based special drug-use surveillance to be conducted in accordance with the GPSP ordinance.
Observational period lasted 24 months from the start of treatment with Kesimpta.
Inclusion Criteria:
Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta
Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients
Exclusion Criteria:
Ohtsu, Shiga 520-2192, Japan
Shimotsuga Gun, Tochigi 321-0293, Japan
Bunkyo Ku, Tokyo 113 8655, Japan
Bunkyo Ku, Tokyo 113-8431, Japan
Minato-ku, Tokyo 105-8471, Japan
Shinjuku Ku, Tokyo 160-0023, Japan
Shinjuku-ku, Tokyo 160 8582, Japan